Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
RAF Proto Oncogene Serine/Threonine Protein Kise (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Overview
RAF Proto Oncogene Serine/Threonine Protein Kise (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
RAF Proto Oncogene Serine/Threonine Protein Kise (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
RAF Proto Oncogene Serine/Threonine Protein Kise (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Apollomics Inc
Basilea Pharmaceutica Ltd
BridgeBio Pharma Inc
Chugai Pharmaceutical Co Ltd
Hanmi Pharmaceuticals Co Ltd
Jazz Pharmaceuticals Plc
Metagone Biotech Inc
Millennium Pharmaceuticals Inc
Novartis AG
Redx Pharma Plc
Samjin Pharm Co Ltd
VG Life Sciences Inc
RAF Proto Oncogene Serine/Threonine Protein Kise (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Drug Profiles
(MG-005 + sorafenib) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(MG-010 + sorafenib) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APL-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAL-3833 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
belvarafenib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CKI-27 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DCBCI-0902 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FYA-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydroxychloroquine + sorafenib tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LXH-254 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REDX-05358 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SJP-1601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit FLT, FLT3, FLT4, FMS, c-KIT, LYN, RAF1, RET, PDGFRa and PDGFRb for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Pan-RAF Kise for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit RAF1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CRAF and BRAF for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Pan-RAF Kise for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Pan-RAF Kise Musculoskeletal Disorders and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-580 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RAF Proto Oncogene Serine/Threonine Protein Kise (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Dormant Products
RAF Proto Oncogene Serine/Threonine Protein Kise (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Discontinued Products
RAF Proto Oncogene Serine/Threonine Protein Kise (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Jun 05, 2019: Belvarafenib confirms efficacy for solid cancer without approved treatment
Apr 01, 2019: Apollomics presents positive preclinical data on APL-102, an oral multi-kise inhibitor with CSF-1R activity
Apr 17, 2018: BT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of Its Multi-Tyrosine Kise Inhibitor, CBT-102, at AACR Annual Meeting 2018
May 05, 2017: Hanmi Pharmaceutical Announced IND Approval of HM95573, a Novel Oral RAF inhibitor
Jan 06, 2017: Hanmi presents pan-RAF inhibitor preclinical trial results at Europe Cancer Symposium
Jun 17, 2016: Hanmi presented the clinical trial results of targeted anti-ancer drug HM95573 at ASCO
Jun 09, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at ASCO meeting
Apr 21, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at AACR meeting
Jun 22, 2015: VG Life Sciences Granted Combition Cancer Drug Patent
Nov 10, 2014: Hanmi To Initiate A Phase 1 Clinical Trial Of HM95573, The Next Generation Targeted Therapy For Melanoma Treatment
Sep 04, 2014: VG Life Sciences Progress Update Phase I Cancer Study
Mar 14, 2014: VG Life Sciences’s Reports on Clinical Outcomes in Phase I Cancer Study
Dec 13, 2013: VG Life Sciences Update on Phase I Cancer Study
Jul 25, 2013: VG Life Sciences Reports on Scientific Advancements: Completion of Third Cohort of Phase I Clinical Trial; Grant from the American Heart Association;
Apr 04, 2013: VG Life Sciences Reports Positive Safety Results Of Hydroxychloroquine And Sorafenib Combition Therapy In Second Cohort Of Phase I Solid Tumor Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Apollomics Inc, H2 2019
Pipeline by Basilea Pharmaceutica Ltd, H2 2019
Pipeline by BridgeBio Pharma Inc, H2 2019
Pipeline by Chugai Pharmaceutical Co Ltd, H2 2019
Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2019
Pipeline by Jazz Pharmaceuticals Plc, H2 2019
Pipeline by Metagone Biotech Inc, H2 2019
Pipeline by Millennium Pharmaceuticals Inc, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Redx Pharma Plc, H2 2019
Pipeline by Samjin Pharm Co Ltd, H2 2019
Pipeline by VG Life Sciences Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019